JP2021520392A5 - - Google Patents
Info
- Publication number
- JP2021520392A5 JP2021520392A5 JP2020554834A JP2020554834A JP2021520392A5 JP 2021520392 A5 JP2021520392 A5 JP 2021520392A5 JP 2020554834 A JP2020554834 A JP 2020554834A JP 2020554834 A JP2020554834 A JP 2020554834A JP 2021520392 A5 JP2021520392 A5 JP 2021520392A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- triazolo
- pyrazolo
- pyrimidine
- furan
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/082140 | 2018-04-08 | ||
| CN2018082140 | 2018-04-08 | ||
| PCT/CN2019/081785 WO2019196803A1 (en) | 2018-04-08 | 2019-04-08 | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520392A JP2021520392A (ja) | 2021-08-19 |
| JP2021520392A5 true JP2021520392A5 (https=) | 2022-04-07 |
| JPWO2019196803A5 JPWO2019196803A5 (https=) | 2022-04-07 |
Family
ID=68163465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554834A Withdrawn JP2021520392A (ja) | 2018-04-08 | 2019-04-08 | Ａ２ａ受容体アンタゴニストとしてのピラゾロトリアゾロピリミジン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11472811B2 (https=) |
| EP (1) | EP3774813A4 (https=) |
| JP (1) | JP2021520392A (https=) |
| KR (1) | KR20200140849A (https=) |
| CN (1) | CN112313234B (https=) |
| AU (1) | AU2019251148A1 (https=) |
| BR (1) | BR112020020078A2 (https=) |
| CA (1) | CA3095839A1 (https=) |
| EA (1) | EA202092036A1 (https=) |
| IL (1) | IL277744A (https=) |
| MX (1) | MX2020010618A (https=) |
| SG (1) | SG11202009706VA (https=) |
| TW (1) | TW202010500A (https=) |
| WO (1) | WO2019196803A1 (https=) |
| ZA (1) | ZA202005772B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020010618A (es) | 2018-04-08 | 2020-11-12 | Beigene Ltd | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. |
| CA3177057A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
| WO2021191376A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
| EP4214200A1 (en) | 2020-10-22 | 2023-07-26 | Nimmune Biopharma, Inc. | Lancl ligands |
| CN113773327B (zh) * | 2021-09-13 | 2022-07-15 | 八叶草健康产业研究院(厦门)有限公司 | 一种吡唑并嘧啶并三唑环类化合物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1283839T1 (https=) * | 2000-05-26 | 2005-08-31 | Schering Corp | |
| AU2002347055B2 (en) | 2001-10-08 | 2006-10-12 | F. Hoffmann-La Roche Ag | Substituted Triazolopyridine Compounds |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| EP1745047B1 (en) | 2004-04-21 | 2010-03-24 | Schering Corporation | Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists |
| CN103261202B (zh) * | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
| WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2017136375A1 (en) | 2016-02-05 | 2017-08-10 | Concert Pharmaceuticals, Inc. | Deuterated tozadenant |
| MX2020010618A (es) | 2018-04-08 | 2020-11-12 | Beigene Ltd | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. |
| CN110742893B (zh) | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
-
2019
- 2019-04-08 MX MX2020010618A patent/MX2020010618A/es unknown
- 2019-04-08 CA CA3095839A patent/CA3095839A1/en active Pending
- 2019-04-08 KR KR1020207031434A patent/KR20200140849A/ko not_active Ceased
- 2019-04-08 AU AU2019251148A patent/AU2019251148A1/en not_active Abandoned
- 2019-04-08 EA EA202092036A patent/EA202092036A1/ru unknown
- 2019-04-08 WO PCT/CN2019/081785 patent/WO2019196803A1/en not_active Ceased
- 2019-04-08 TW TW108112189A patent/TW202010500A/zh unknown
- 2019-04-08 EP EP19785064.7A patent/EP3774813A4/en not_active Withdrawn
- 2019-04-08 SG SG11202009706VA patent/SG11202009706VA/en unknown
- 2019-04-08 JP JP2020554834A patent/JP2021520392A/ja not_active Withdrawn
- 2019-04-08 BR BR112020020078-6A patent/BR112020020078A2/pt not_active IP Right Cessation
- 2019-04-08 CN CN201980024422.3A patent/CN112313234B/zh not_active Expired - Fee Related
- 2019-04-08 US US16/982,681 patent/US11472811B2/en active Active
-
2020
- 2020-09-17 ZA ZA2020/05772A patent/ZA202005772B/en unknown
- 2020-10-01 IL IL277744A patent/IL277744A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520392A5 (https=) | ||
| JP2008534496A5 (https=) | ||
| JP2021500345A5 (https=) | ||
| DK3072886T3 (en) | Pyridine-2-amides for use as CB2 agonists | |
| RU2008148902A (ru) | Производные имидазол-пиримидина для лечения заболеваний, связанных с киназой гликогенсинтазы 3 (gsk3) | |
| JP2017510555A5 (https=) | ||
| ME01507B (me) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
| JP2013542265A5 (https=) | ||
| JP2019504901A5 (https=) | ||
| JP2009542638A5 (https=) | ||
| JP2012502975A5 (https=) | ||
| JP2009542721A5 (https=) | ||
| JP2016536333A5 (https=) | ||
| JP2014523851A5 (https=) | ||
| JP2018511587A5 (https=) | ||
| JP2016523911A5 (https=) | ||
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| CN101605540A (zh) | 使用mek抑制剂的方法 | |
| RU2004118719A (ru) | Производные пиперидин-2-она и фармацевтические композиции, содержащие такие соединения в качестве активного ингредиента | |
| JP2018530591A5 (https=) | ||
| RU2011137399A (ru) | Гетероциклическое производное | |
| JP2017500364A5 (https=) | ||
| JP2017523215A5 (https=) | ||
| RU2014150049A (ru) | Ингибиторы nampt | |
| RU2018127315A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний |